<DOC>
	<DOCNO>NCT02091882</DOCNO>
	<brief_summary>The purpose study determine accuracy IEM detection MIND1 System complete series Patch application IEM ingestion clinic .</brief_summary>
	<brief_title>Substudy Accuracy Ingestible Event Marker ( IEM ) Detection Medical Information Device # 1 ( MIND1 )</brief_title>
	<detailed_description>The OSMITTER study protocol design master protocol govern multiple substudies rapid assessment candidate subcomponents MIND1 System . This substudy conduct determine accuracy IEM detection MIND1 System complete series Patch application IEM ingestion clinic . Following placement Patch clinic staff , subject ingest one tablet approximately every 2 hour , total 4 ingestion . Aripiprazole-embedded IEM tablet test along placebo-embedded IEM tablet assess difference accuracy IEM detection latency . Approximately 32 healthy volunteer subject enrol substudy . The duration substudy subject estimate 1 day active participation plus 2-week safety follow ( phone call ) period .</detailed_description>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Healthy male healthy nonpregnant female 18 65 year age time informed consent willing either practice abstinence 2 barrier method birth control 1 barrier method oral contraceptive method Subject must good general health ( suffer serious chronic mental physical disorder require may near future require urgent medical care ) Body mass index 19 32 kg/m2 ( inclusive ) Ability eat high fat meal Subject history skin sensitivity adhesive medical tape metal . Subject , opinion investigator , acutely psychotic manic symptom currently require hospitalization Subject history evidence medical condition would expose undue risk significant adverse event ( AE ) interfere assessment safety course trial Subject receive investigational product within last 30 day . Subject current history drug alcohol dependence meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion Subject presence cognitive impairment Subject currently take antipsychotic medication Subject terminal illness Subject history chronic dermatitis Subject history gastrointestinal surgery could impair absorption Female subject breastfeed and/or positive serum pregnancy test result prior receive trial medication Sexually active woman childbearing potential ( WOCBP ) commit use 2 form approve birth control method remain abstinent trial 30 day follow last dose trial medication Sexually active male commit use 2 approved birth control method remain abstinent duration trial 90 day follow last dose trial medication No permanent physical residence After rest ≥ 3 minute , sit systolic blood pressure &lt; 100 ≥ 150 mmHg and/or diastolic blood pressure &lt; 50 ≥ 90 mmHg After rest ≥ 3 minute , sit pulse rate &lt; 35 &gt; 100 beat per minute Any subject , opinion investigator , participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>OPC-14597 Digital</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Medical Information Device # 1 System ( MIND1 )</keyword>
	<keyword>Ingestible Event Marker</keyword>
</DOC>